Veterinary Medicines

EURICAN DAPPI LYOPHILISATE AND SOLVENT FOR SUSPENSION FOR INJECTION

Authorised
  • Canine parainfluenza virus, strain CGF 2004/75, Live
  • Canine distemper virus, strain BA5, Live
  • Canine parvovirus, strain CAG2, Live
  • Canine adenovirus 2, strain DK13, Live
Download as PDF

Product identification

Medicine name:
EURICAN DAPPI LYOPHILISATE AND SOLVENT FOR SUSPENSION FOR INJECTION
Eurican DAPPi
Active substance:
  • Canine parainfluenza virus, strain CGF 2004/75, Live
  • Canine distemper virus, strain BA5, Live
  • Canine parvovirus, strain CAG2, Live
  • Canine adenovirus 2, strain DK13, Live
Target species:
  • Dog
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Canine parainfluenza virus, strain CGF 2004/75, Live
    4.70
    log10 50% cell culture infectious dose
    /
    1.00
    Dose
  • Canine distemper virus, strain BA5, Live
    4.00
    log10 50% cell culture infectious dose
    /
    1.00
    Dose
  • Canine parvovirus, strain CAG2, Live
    4.90
    log10 50% cell culture infectious dose
    /
    1.00
    Dose
  • Canine adenovirus 2, strain DK13, Live
    2.50
    log10 50% cell culture infectious dose
    /
    1.00
    Dose
Pharmaceutical form:
  • Lyophilisate and solvent for suspension for injection
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI07AD04
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Germany
Available in:
  • Germany
Package description:
  • Plastic box of 10 vials of lyophilisate (1 dose)
  • Plastic box of 50 vials of lyophilisate (1 dose)
  • Plastic box of 100 vials of lyophilisate (1 dose)
  • Plastic box of 10 vials of solvent (1 ml)
  • Plastic box of 50 vials of solvent (1 ml)
  • Plastic box of 100 vials of solvent (1 ml)
  • Plastic box of 10 vials of lyophilisate (1 dose) and 10 vials of solvent (1 ml)
  • Plastic box of 100 vials of lyophilisate (1 dose) and 100 vials of solvent (1 ml)
  • Plastic box of 50 vials of lyophilisate (1 dose) and 50 vials of solvent (1 ml)

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application - Known active substance (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Boehringer Ingelheim Vetmedica GmbH
Marketing authorisation date:
Manufacturing sites for batch release:
  • Boehringer Ingelheim Animal Health France
Responsible authority:
  • Paul-Ehrlich-Institut
Authorisation number:
  • PEI.V.11828.01.1
Date of authorisation status change:
Reference member state:
  • France
Procedure number:
  • FR/V/0306/001
Concerned member states:
  • Austria
  • Belgium
  • Bulgaria
  • Croatia
  • Cyprus
  • Czechia
  • Denmark
  • Estonia
  • Finland
  • Germany
  • Greece
  • Hungary
  • Ireland
  • Italy
  • Latvia
  • Lithuania
  • Luxembourg
  • Malta
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Slovenia
  • Spain
  • Sweden
  • United Kingdom (Northern Ireland)

Documents

Combined File of all Documents

This document does not exist in this language (English). You can find it in another language below.
German (PDF)
Published on: 18/04/2024
Download

2613646-paren-20160224.pdf.pdf

English (PDF)
Published on: 17/09/2024
Download